Project: Development of Novel Targeted Drugs for Treatment of Liver Fibrosis

Acronym DeFiber (Reference Number: 12350)
Duration 01/10/2018
Project Topic The aim is to develop the first targeted treatment for patients suffering from liver fibrosis (LF). The approach is based on a nanobody-drug-conjugate (NDC), targeted to hepatic stellate cells (HSC), by linking HSC-specific nanobodies to a fibrotic scar diminishing drug, using the proprietary Lx-linker, together called LxL-LF. DeFiber aims to select the best LxL-LF candidate based on in vitro and in vivo studies, and to develop complementary diagnostics, preparing for the (pre-)clinical phases.
Network Eurostars 2
Call Eurostars Cut–off 9

Project partner

Number Name Role Country
1 LinXis Pharmaceuticals B.V. Coordinator Netherlands
2 ChemCon GmbH Partner Germany
3 Universitatsklinikum Bonn Partner Germany